Abstract 280P
Background
HER2DX test is a genomic assay that evaluates the expression of 27 genes across four signatures (proliferation, luminal, immune and HER2 amplicon). The test provides prognostic (HER2DX risk score), predictive (HER2DX pathological complete response (pCR) score) information and levels of ERBB2 expression (ERBB2-score) in HER2+ early breast cancer (BC). We outline the preliminary results from the ongoing decision impact study of HER2DX at Valencia.
Methods
We conducted an observational, prospective, pilot, multicentric study involving 10 hospitals since Feb-23 (ongoing) to evaluate the clinical utility of HER2DX in early-stage HER2+ BC patients (pts). The main objective was to assess the % of change in the therapeutic plan after obtaining the HER2DX report.
Results
We analyzed the first consecutive 66 HER2DX tests performed. Median age was 54 years (range 28-79). The majority of pts were classified as stage II (66.7%), follow by stage I (19.7%), and stage III (13.6%). Luminal-HER2+ represented 66.7% of cases, and median ki67 was 30% (range 10-95%). Notably, 15.2% of test were conducted post-surgery. Among stage II, 50% of pts presented a high relapse risk, while, only 23.1% of stage I and 88.9% of stage III were considered high risk. A change in the treatment plan before and after the HER2DX result was observed in 27 of 66 (40.9%) cases, with 67.9% of the cases involving pts diagnosed at stage II. De-escalation of therapy was observed in 92.3% of pts (less poly-chemotherapy).
Conclusions
Our findings demonstrate the significant impact of HER2DX on clinical management decisions in early HER2+ BC, prompting oncologist to modify treatment strategies based on its results.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
312P - Early detection of metastatic disease in asymptomatic early-stage breast cancer patients using imaging: A cross-sectional analytic study at a tertiary hospital
Presenter: John kelvin Lalusis
Session: Poster session 14
313P - A longitudinal follow-up study on the prognosis of patients with breast cancer with delayed diagnosis during the COVID-19 pandemic
Presenter: Jae Pak Yi
Session: Poster session 14
314P - The impact of changes in tumor mutational landscape during neoadjuvant therapy on tumor-informed ctDNA testing in breast cancer patients
Presenter: Mark Magbanua
Session: Poster session 14
315P - Long-term tamoxifen benefit in pre- and postmenopausal patients of high and low risk with luminal A and B breast cancer
Presenter: Oscar Danielsson
Session: Poster session 14
316P - Differential long-term benefit of 2-year adjuvant tamoxifen therapy for luminal-type breast cancer: Insights from a 20-year follow-up analysis of the STO trials
Presenter: Magdalena Rios Romero
Session: Poster session 14
317TiP - A randomized, multicenter, open-label phase II neoadjuvant study to evaluate the safety and efficacy of HER2-ADC disitamab vedotin in combination toripalimab or sequence chemotherapy in participants with HR-negative, HER2 low-expressing breast cancer
Presenter: Zhimin Shao
Session: Poster session 14
318TiP - Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in stage II-III HER2-positive breast cancer: The TRAIN-4 study
Presenter: Fleur Louis
Session: Poster session 14
319TiP - NeoBREASTIM: A phase II study of atezolizumab plus RP1 oncolytic immunotherapy in the neoadjuvant setting of triple-negative breast cancer (TNBC)
Presenter: Etienne Bastien
Session: Poster session 14
321P - Sentinel lymph node biopsy in clinical T3-4c breast cancer: A retrospective multicenter cohort study
Presenter: Yasuaki Sagara
Session: Poster session 14
322P - Incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021
Presenter: Alexandra Thomas
Session: Poster session 14